Millipore Sigma Vibrant Logo

204876 Complement C1q, Human

Complement C1q, Human, CAS 80295-33-6, is a native C1q complement component composed of 18 polypeptide chains consisting of three nonidentical A, B, C subunits of 29, 26, and 19 kDa, respectively.

Complement C1q, Human: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
View Products on Sigmaaldrich.com
204876
Ver precios y disponibilidad

Descripción

Replacement Information

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
204876-1MG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 1 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewNative, human C1q complement component. Glycoprotein composed of 18 polypeptide chains consisting of three nonidentical subunits, A, B, and C, of M.W. 29 kDa, 26 kDa, and 19 kDa, respectively. Present in normal human serum at 70 µg/ml. Found in circulating blood plasma complexed with two C1r and two C1s molecules to form the first component of complement (C1). Activation of complement via classical pathway is triggered by binding of C1q to immune complexes containing IgG or IgM or to a variety of other activating substances, including C-reactive protein, retroviruses, and mitochondria. Subsequent to C1q binding, C1r and C1s are converted to proteolytic enzymes that are responsible for continuation of activation via the classical pathway.
      Catalogue Number204876
      Brand Family Calbiochem®
      References
      ReferencesLoos, M., et al. 1980. J. Immunol. 124, 59.
      Kolb, W.P., et al. 1979. J. Immunol. 122, 2103.
      Product Information
      CAS number80295-33-6
      FormLiquid
      FormulationIn 300 mM NaCl, 10 mM HEPES, 40% glycerol, pH 7.2.
      Quality LevelMQ200
      Applications
      Biological Information
      Biological activity≥150,000 C1qH50 units/mg and ≥70% C1q activity in normal human serum on a mg/mg basis
      Purity≥90% by SDS-PAGE
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      ContaminantsIgG, IgA, IgM, C3, C4, albumin, fibrinogen, α₂-macroglobulin: ≤trace amounts
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      204876-1MG 04055977219685

      Documentation

      Complement C1q, Human Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Complement C1q, Human Certificados de análisis

      CargoNúmero de lote
      204876

      Referencias bibliográficas

      Visión general referencias
      Loos, M., et al. 1980. J. Immunol. 124, 59.
      Kolb, W.P., et al. 1979. J. Immunol. 122, 2103.

      Citas

      Título
    • Baruah, P., et al. 2006. Journal of Leukocyte Biology in press,.
    • Yuste, J., et al. 2006. Journal of Immunology 176, 6112.
      		•
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-May-2008 RFH
      DescriptionNative, human C1q complement component. Glycoprotein composed of 18 polypeptide chains consisting of three nonidentical subunits A, B, and C, of M.W. 29,000, 26,000 and 19,000, respectively. Present in normal human serum at 70 µg/ml. Found in circulating blood plasma complexed with two C1r and two C1s molecules to form the first component of complement (C1). Activation of complement via classical pathway is triggered by binding of C1q to immune complexes containing IgG or IgM or to a variety of other activating substances, including C-reactive protein, retroviruses, and mitochondria. Subsequent to C1q binding, C1r and C1s are converted to proteolytic enzymes that are responsible for continuation of activation via the classical pathway.
      FormLiquid
      FormulationIn 300 mM NaCl, 10 mM HEPES, 40% glycerol, pH 7.2.
      Concentration Label Please refer to vial label for lot-specific concentration
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      CAS number80295-33-6
      Purity≥90% by SDS-PAGE
      ContaminantsIgG, IgA, IgM, C3, C4, albumin, fibrinogen, α₂-macroglobulin: ≤trace amounts
      Biological activity≥150,000 C1qH50 units/mg and ≥70% C1q activity in normal human serum on a mg/mg basis
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesLoos, M., et al. 1980. J. Immunol. 124, 59.
      Kolb, W.P., et al. 1979. J. Immunol. 122, 2103.
      Citation
    • Baruah, P., et al. 2006. Journal of Leukocyte Biology in press,.
    • Yuste, J., et al. 2006. Journal of Immunology 176, 6112.
      		•